Pfizer Reports P-III (MATISSE) Trial Results of RSVpreF for the Treatment of Respiratory Syncytial Virus
Shots:
- The P-III (MATISSE) trial evaluated the efficacy, safety, and immunogenicity of RSVpreF (120µg) vs PBO in a ratio (1:1) in 7400 patients aged ≤49yrs. with RSV
- The results showed the vaccine efficacy of 81.8% & 57.1 against sev. MA-LRTI & MA-LRTI due to RSV in infants from birth through the first 90 days of life with 69.4% & 51.3% high efficacy over 6mos. follow-up period. The vaccine was well-tolerated with no safety concerns for vaccinated individuals and newborns
- The results met one of the study protocol’s pre-specified regulatory success criteria. The company is expected to submit a BLA to the US FDA at the end of 2022, followed by other regulatory authorities in the coming months
Ref: Businesswire | Image: Pfizer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
